期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

异基因造血干细胞移植治疗外周T细胞淋巴瘤研究进展 被引量：2

Progress on allogeneic hematopoietic stem cell transplantation in peripheral T cell lymphoma
原文传递
导出
摘要 外周T细胞淋巴瘤（peripheral T cell lymphoma，PTCL）是起源于胸腺后或成熟T细胞的一组异质性淋巴瘤，不同地区其发生率有明显差异，在西亚等国家占非霍奇金淋巴瘤（NHL）不到20％，而在东亚地区达到22％～32．5％，其中中国所占比例最高（达30％以上）。
作者 尹光丽 李建勇 缪扣荣
机构地区 南京医科大学第一附属医院、江苏省人民医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第4期343-347,共5页 Chinese Journal of Hematology
关键词 外周T细胞淋巴瘤 异基因造血干细胞 移植治疗 LYMPHOMA 非霍奇金淋巴瘤 CELL 东亚地区 异质性
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献47

  • 1Park S, Ko YH. Peripheral T cell lymphoma in Asia [J]. Int J Hematol, 2014, 99(3):227-239. doi: 10.1007/s12185-014-1520- 3.
  • 2Savage K J, Harris NL, Vose JM, et al. ALK- anaplastic large- cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T- Cell Lymphoma Project [J]. Blood, 2008, 111 (12) :5496- 5504. doi: 10.1182/blood-2008-01-134270.
  • 3Rodriguez J, Conde E, Guti6rrez A, et al. The adjusted Interna- tional Prognostic Index and beta-2-microglobulin predict the out-come after autologous stem cell transplantation in relapsing/re- fractory peripheral T-cell lymphoma [J]. Haematologica, 2007, 92(8):1067-1074.
  • 4Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostica- tion in the modem era including impact of frontline therapy [J]. Ann Oncol, 2014, 25 (11):2211-2217. dot: 10.1093/annonc/ mdu443.
  • 5Briski R, Feldman AL, Bailey NG, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T- cell lymphomas [J]. Blood Cancer J, 2014, 4:e214. dot: 10.1038/bcj.2014.34.
  • 6Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage Ill/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial[J]. Eur J Cancer, 2012, 48(17):3223-3231. dot: 10.1016/j. ejca.2012.06.003.
  • 7Gkotzamanidou M, Papadimitriou CA. Peripheral T-cell lympho- ma: the role of hematopoietic stem cell transplantation [J]. Crit Rev Oncol Hematol, 2014, 89 (2):248-261. doi: 10.1016/j.crit- revonc.2013.08.016.
  • 8Le GS, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci6t6 Francaise de Greffe de Mo6lle et de Th6rapie Cellulaire [J]. J Clin Oncol, 2008, 26 (14):2264-2271. doi: I0.1200/ JCO.2007.14.1366.
  • 9Corradini P, Vitolo U, Rambaldi A, et al. Intensified chemo- immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma [J]. Leukemia, 2014, 28(9):1885-1891. doi: 10.1038/leu.2014.79.
  • 10Beitinjaneh A, Saliba RM, Okoroji GJ, et al. Autologous and allogeneic stem cell transplantation for T-Cell lymphoma: The MD Anderson Cancer Center experience [J]. Blood, 2014, 18: Abstr 4118.

二级参考文献44

  • 1Savage KJ. Peripheral T-cell lymphomas [J]. Blood Rev, 2007, 21(4):201-216.
  • 2Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes [J]. J Clin Oncol, 2008, 26(25): 4124-4130.
  • 3Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American insti- tution by the WHO classification [ J ]. Ann Oncol, 2004, 15 (10): 1467-1475.
  • 4Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group [ J ]. Blood, 2010, 116( 18):3418-3425.
  • 5Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treat- ment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience[J]. Cancer, 2005, 103( 10): 2091-2098.
  • 6Dunleavy K, Shovlin M, Pittaluga S, et al. DA-EPOCH chemo- therapy is highly effective in ALK-positive and ALK-negative ALCL: results of a prospective study of PTCL subtypes in adults [J]. Blood, 2011, liB:Abstract 1618.
  • 7Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase Ⅱ study [J]. Cancer Chemother Pharmacol, 2007, 60( 1 ):129-134.
  • 8Gallamini A, Zaja F, Patti C, et al. Alemtuzumah (Campath-Ⅲ) and CHOP chemotherapy as first- line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multieenter trial[J]. Blood, 2007, 110(7):2316-2323.
  • 9Janik J, Dunleauy K, Pittaluga S, et al. A pilot study of Campath- 1 with dose-adjusted EPOCH in CD52 expressing aggressive T- cell malignancies[J]. Blood, 2005, 106: Abstract 33348.
  • 10Foss FM, Sjak-Shie N, Goy A, et al. A multicenter phase Ⅱ trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study [J] . Leuk Lymphoma, 2013, 54(7):1373-1379.

共引文献30

同被引文献9

引证文献2

二级引证文献1

中华血液学杂志
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部